A high performing alternative to Cas9
Inscripta developed and released the MAD7® nuclease to the global research community in 2017 under a broad technology access program.
Inscripta now offers a portfolio of MADzymeTM nucleases under an expanded, non-exclusive licensing program including several MAD variants with improved properties
such as expanded PAM sites, altered activity profiles and higher fidelity. Please contact us below to learn more.
Wild type MAD7® protein is now available as an off-the-shelf product from our trusted partners at Aldevron. See the press release.